Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Cash & Current Investments (2016 - 2025)

Anaptysbio filings provide 10 years of Cash & Current Investments readings, the most recent being $311.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 19.13% year-over-year to $311.6 million, compared with a TTM value of $311.6 million through Dec 2025, down 19.13%, and an annual FY2025 reading of $311.6 million, down 19.13% over the prior year.
  • Cash & Current Investments hit $311.6 million in Q4 2025 for Anaptysbio, up from $249.0 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $548.1 million in Q4 2021, with the low at $249.0 million in Q3 2025.
  • Median Cash & Current Investments over the past 5 years was $390.9 million (2021), compared with a mean of $392.0 million.
  • The sharpest move saw Cash & Current Investments skyrocketed 39.23% in 2021, then tumbled 42.12% in 2025.
  • Year by year, Cash & Current Investments stood at $548.1 million in 2021, then dropped by 19.5% to $441.2 million in 2022, then dropped by 11.41% to $390.9 million in 2023, then fell by 1.41% to $385.4 million in 2024, then fell by 19.13% to $311.6 million in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $311.6 million, $249.0 million, and $265.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.